VISEN PHARMA-B Raises Connected-Transaction Caps to RMB270.61 Million for 2026-2028, Citing Commercialisation Needs

Bulletin Express03-26

VISEN Pharmaceuticals (VISEN PHARMA-B, 02561) has proposed sizeable increases to three sets of annual caps governing continuing connected transactions with Ascendis Pharma A/S subsidiaries, reflecting higher resource needs ahead of lonapegsomatropin’s commercial launch and other pipeline milestones.

Key Changes

1. Exclusive Licence Framework Agreement (ELA) • 2026 cap lifted to RMB39.31 million from RMB23.65 million. • New future caps: RMB36.95 million for 2027 and RMB22.98 million for 2028. • Drivers: additional full-time equivalent (FTE) support for technology transfer and commercial supply chain set-up, plus extra materials for localisation.

2. 1st Commercial Supply Framework Agreement (CSA) • 2026 cap raised sharply to RMB76.90 million from RMB4.00 million. • 2027 cap set at RMB4.56 million. • Reason: shipment schedule for lonapegsomatropin drug packages pushed from 2025 into 2026-2027; RMB42.20 million of pre-payments already made by 31 Dec 2025.

3. 2nd Commercial Supply Framework Agreement (CSFA) • 2026 cap increased to RMB154.40 million from RMB52.20 million. • 2027 cap increased to RMB164.20 million from RMB88.60 million. • Reason: deliveries of drug packages, auto-injectors and ancillary products now expected to start in 2026; RMB194.40 million pre-paid as at end-2025.

Regulatory & Governance

• All Ascendis entities are connected persons; each revised cap exceeds the 5% percentage ratio under HKEX Chapter 14A, triggering disclosure, circular and independent shareholders’ approval requirements. • An extraordinary general meeting is scheduled for 22 Apr 2026; Ascendis-affiliated shareholders will abstain from voting. • No directors have material interests in the transactions.

Internal Controls

VISEN will enhance monitoring by: • Bi-annual connected-transaction reports; • Benchmarking FTE rates and pass-through costs; • Independent audits of purchase prices; • Alerts when utilisation reaches 75% of any cap.

Impact

Management states the revisions align with updated R&D and commercial timelines and do not materially affect operations or finances. The transactions remain on normal commercial terms, subject to independent shareholders’ approval.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment